择期肾下腹主动脉瘤腔内修复术后术者经验的影响:顾问医师与受监督培训医师的短期至中期结局
该单中心回顾性比较研究纳入2011-2023年507例择期肾下腹主动脉瘤腔内修复(EVAR)患者,比较受监督培训医师(ST)与顾问医师(C)作为主要术者的结局。30天主要不良事件(MAE)发生率ST组7.0% vs C组9.9%(p=0.31,aOR=0.94,95%CI 0.46-1.91),各次要结局调整后均无显著差异。作者认为在精心选择的病例中,受监督培训医师施行择期EVAR的中期安全性和有效性与顾问医师相当,但需进一步研究确认。
要点
- 507例择期肾下EVAR中,受监督培训医师组与顾问医师组的30天MAE发生率无显著差异。
- 造影剂用量、手术时间、出血、ICU入住、住院时间、重返手术室及中期免于主动脉相关干预调整后均无显著差异。
- 作者认为精心选择的病例中受监督培训医师施行择期EVAR似乎安全有效,仍需进一步研究确认。
核心结论
- 在精心选择的病例中,受监督培训医师施行择期EVAR的中期安全性和有效性似乎与顾问医师相当。
- 这些发现可能对培训项目有重要意义,但需进一步研究确认和阐明。
研究设计与样本
- 单中心回顾性比较研究,纳入2011-2023年所有连续接受择期EVAR的患者。
- 共纳入507例患者,按主要术者经验分为受监督培训医师(ST)组62.1%与顾问医师(C)组32.5%。
- 主要结局为30天主要不良事件(MAE)发生率,次要结局包括造影剂用量、手术时间、出血、住院时间、重返手术室及至2年免于主动脉相关干预。
主要发现
- 72例MAE发生于8.1%的患者,组间无差异(ST组7.0% vs C组9.9%,p=0.31,aOR=0.94,95%CI 0.46-1.91),MAE各组分单独分析亦无差异。
- 调整混杂后,造影剂用量≥120 mL(aOR=0.89,95%CI 0.50-1.56)、手术时间≥160分钟(aOR=0.73,95%CI 0.45-0.18)、出血(aOR=1.13,95%CI 0.60-2.12)、ICU入住(aOR=0.68,95%CI 0.40-1.17)、住院时间延长(aOR=0.93,95%CI 0.60-1.43)、重返手术室(aOR=0.91,95%CI 0.37-2.20)均无显著差异。
- 中期免于主动脉相关干预无显著差异(aHR=1.39,95%CI 0.69-2.79)。
临床怎么用
- 作者认为在精心选择的病例中,由受监督培训医师施行择期EVAR似乎安全有效,可能对血管培训项目有重要意义。
- 作者指出需进一步研究确认和阐明上述发现。
局限性
- 原文报告需进一步研究以确认和阐明这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vascular trainees are required to have a comprehensive training program, encompassing the completion of clinical, surgical, and research tasks. To fulfill their surgical abilities and performance, sufficient supervised operating time is mandatory. After open vascular procedures, it has been observed that trainee involvement does not lead to detrimental outcomes. On the contrary, its impact during endovascular procedures, which require distinct technical skills, is scarcely reported. The authors aim to analyze the impact of primary operator experience on the outcomes of elective infrarenal endovascular aneurysm repair (EVAR) performed within a teaching institution over a 14-year period. METHODS: This is a single-center, retrospective, comparative study. All consecutive patients submitted to elective EVAR (2011-2023) were considered. Two groups were defined: supervised trainee (ST) and consultant (C), according to the experience of the primary operator. The primary outcome was the incidence of 30-day major adverse events (MAEs). The secondary outcomes were contrast usage, operative time, bleeding, length of stay (LOS), return to operating room (OR), and freedom from aortic-related interventions up to 2 years. RESULTS: Overall, 507 patients were included (62.1% ST vs 32.5% C). Seventy-two MAEs occurred in 8.1%, with no differences across groups (7.0% ST vs 9.9% C, p=0.31, adjusted odds ratio [aOR]=0.94, 95% confidence interval [CI]=0.46-1.91 for ST-performed procedures), even when MAE components were depicted individually. After adjustment for confounders, no significant differences were found in contrast usage ≥120 mL (aOR=0.89, 95% CI=0.50-1.56), operative time ≥160 minutes (aOR=0.73, 95% CI=0.45-0.18), bleeding (aOR=1.13, 95% CI=0.60-2.12), intensive care unit admission (aOR=0.68, 95% CI=0.40-1.17), prolonged LOS (aOR=0.93, 95% CI=0.60-1.43), return to OR (aOR=0.91, 95% CI=0.37-2.20), and mid-term freedom from aortic-related interventions (adjusted hazard ratio [aHR]=1.39, 95% CI=0.69-2.79). CONCLUSION: In carefully selected cases, elective EVAR performed by supervised trainees seems as safe and effective at mid-term as operations performed by consultants. These findings may have important implications for training programs. Further studies to confirm and clarify our findings are required.Clinical ImpactIn carefully selected cases, elective EVAR performed by supervised trainees seems safe, when compared to operations performed by consultants. Short-term major adverse events, contrast usage, operative time, bleeding, secondary interventions and length of stay appear similar. Mid-term freedom-from aortic interventions is comparable. These findings may have important implications for vascular training programs.
引用
- Ribeiro TF, Fidalgo H, Soares Ferreira R, et al. The Impact of Surgeon Experience-Consultant Versus Supervised Trainees After Elective Infrarenal EVAR: Short-term to Mid-term Outcomes. J Endovasc Ther. 2025. PMID: 39878122. doi:10.1177/15266028251313955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。